CDT EQUITY INC. Current Liabilities
CDT EQUITY INC. (CDT) had Current Liabilities of $23.35 million as of 2026-06-30, per its S-1 filed 2026-09-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-09-08
- 2026-06-30: Liabilities, Current $23.35M.
- 2026-03-31: Liabilities, Current $21.64M.
- 2025-12-31: Liabilities, Current $12.82M.
- 2025-09-30: Liabilities, Current $4.26M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $23.35M S-1 · filed 2026-09-08 | |
| 2026-03-31 | $21.64M 10-Q · filed 2026-07-15 | |
| 2025-12-31 | $12.82M S-1 · filed 2026-09-08 | |
| 2025-09-30 | $4.26M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $4.41M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $4.55M 10-Q/A · filed 2025-08-14 | |
| 2024-12-31 | $10.74M S-1 · filed 2026-09-08 | |
| 2024-09-30 | $11.98M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $8.59M 10-Q/A · filed 2024-11-14 | $2.86M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $7.72M 10-Q/A · filed 2024-11-14 | $1.98M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $1.80M 10-K · filed 2025-03-28 | |
| 2023-09-30 | $4.60M 10-Q/A · filed 2023-11-21 | |
| 2023-06-30 | $5.98M 10-Q/A · filed 2024-11-14 | $2.03M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.96M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $4.18M 10-K · filed 2024-04-16 | $417.98K 10-K · filed 2023-03-28 |
| 2022-09-30 | $316.13K 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $138.65K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $78.36K 10-Q · filed 2022-05-18 | |
| 2021-12-31 | $192.51K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |